The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Comprehensive Transcriptome and Mutational Profiling of Endemic Burkitt Lymphoma Reveals EBV Type–Specific Differences
Open accessPublished version of a preprint
Abstract
Endemic Burkitt lymphoma (eBL) is the most common pediatric cancer in malaria-endemic equatorial Africa and nearly always contains Epstein–Barr virus (EBV), unlike sporadic Burkitt lymphoma (sBL) that occurs with a lower incidence in developed countries. Given these differences and the variable clinical presentation and outcomes, we sought to further understand pathogenesis by investigating transcriptomes using RNA sequencing (RNAseq) from multiple primary eBL tumors compared with sBL tumors. Within eBL tumors, minimal expression differences were found based on: anatomical presentation site, in-hospital survival rates, and EBV genome type, suggesting that eBL tumors are homogeneous without marked subtypes. The outstanding difference detected using surrogate variable analysis was the significantly decreased expression of key genes in the immunoproteasome complex (PSMB9/β1i, PSMB10/β2i, PSMB8/β5i, and PSME2/PA28β) in eBL tumors carrying type 2 EBV compared with type 1 EBV. Second, in comparison with previously published pediatric sBL specimens, the majority of the expression and pathway differences was related to the PTEN/PI3K/mTOR signaling pathway and was correlated most strongly with EBV status rather than geographic designation. Third, common mutations were observed significantly less frequently in eBL tumors harboring EBV type 1, with mutation frequencies similar between tumors with EBV type 2 and without EBV. In addition to the previously reported genes, a set of new genes mutated in BL, including TFAP4, MSH6, PRRC2C, BCL7A, FOXO1, PLCG2, PRKDC, RAD50, and RPRD2, were identified. Overall, these data establish that EBV, particularly EBV type 1, supports BL oncogenesis, alleviating the need for certain driver mutations in the human genome. Implications: Genomic and mutational analyses of Burkitt lymphoma tumors identify key differences based on viral content and clinical outcomes suggesting new avenues for the development of prognostic molecular biomarkers and therapeutic interventions. Mol Cancer Res; 15(5); 563–76. ©2017 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“In addition, an RNA-seq study of patient tumors of EBL, a common childhood cancer from equatorial Africa where malaria is endemic, showed that the vast majority of cases which harbor EBV contain PLCγ2 mutations, along with mutations in other genes including MYC (142).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [142]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Interestingly, while MYC translocation and hyperexpression is a hallmark of EBL, it in itself is not sufficient to induce lymphogenesis (143), which may at least in part explain why mutations in PLCγ2 are relevant to the disease initiation (142).”
From The role of PLCγ2 in immunological disorders, cancer, and neurodegeneration (2021) · cites this paper as [142]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data
McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010) · Genome Research · doi:10.1101/gr.107524.110 · Cited by 27,895
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Li, B., & Dewey, C. N. (2011) · BMC Bioinformatics · doi:10.1186/1471-2105-12-323 · Cited by 22,179
Molecular signatures database (MSigDB) 3.0
Liberzon, A., Subramanian, A., Pinchback, R., Thorvaldsdóttir, H., Tamayo, P., & Mesirov, J. P. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr260 · Cited by 7,111
Kadoch, C., Hargreaves, D. C., Hodges, H. C., Elias, L., Ho, L., Ranish, J. A., & Crabtree, G. R. (2013) · Nature Genetics · doi:10.1038/ng.2628 · Cited by 1,493
Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics
Schmitz, R., Young, R. M., Ceribelli, M., Jhavar, S. G., Xiao, W., Zhang, M., Wright, G. W., Shaffer, A. L., Hodson, D. J., Buras, E. D., et al. (2012) · Nature · doi:10.1038/nature11378 · Cited by 935
Landscape of genomic alterations in cervical carcinomas
Ojesina, A. I., Lichtenstein, L., Freeman, S. S., Pedamallu, C. S., Imaz-Rosshandler, I., Pugh, T. J., Cherniack, A. D., Ambrogio, L., Cibulskis, K., Bertelsen, B. I., et al. (2013) · Nature · doi:10.1038/nature12881 · Cited by 874
Rowe, M., Rowe, D., Gregory, C. D., Young, L. S., Farrell, P. J., Rupani, H., & Rickinson, A. B. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02568.x · Cited by 711
The genetic landscape of mutations in Burkitt lymphoma
Love, C., Sun, Z., Jima, D. D., Li, G., Zhang, J., Miles, R. R., Richards, K. L., Dunphy, C. H., Choi, W. W. L., Srivastava, G., et al. (2012) · Nature Genetics · doi:10.1038/ng.2468 · Cited by 609
svaseq: removing batch effects and other unwanted noise from sequencing data
Leek, J. T. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku864 · Cited by 551
Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation.
Cohen, J. I., Wang, F., Mannick, J. B., & Kieff, E. D. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.23.9558 · Cited by 483
the ICGC MMML-Seq Project (2012) · Nature Genetics · doi:10.1038/ng.2469 · Cited by 435
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Morin, R. D., Mungall, K., Pleasance, E., Mungall, A. J. J., Goya, R., Huff, R. D., Scott, D. W., Ding, J., Roth, A. J. L., Chiu, R., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483727 · Cited by 407
U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.
Dambaugh, T. R., Hennessy, K., Chamnankit, L., & Kieff, E. D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.23.7632 · Cited by 383
Abbas, A. R., Baldwin, D. T., Ma, Y., Ouyang, W., Gurney, A. L., Martin, F., Fong, S. S., Campagne, M. V. L., Godowski, P. J., Williams, P. M., et al. (2005) · Genes and Immunity · doi:10.1038/sj.gene.6364173 · Cited by 377
Burkitt's Lymphoma: Clinicopathologic Features and Differential Diagnosis
Ferry, J. A. (2006) · The Oncologist · doi:10.1634/theoncologist.11-4-375 · Cited by 377
The genomic landscape of nasopharyngeal carcinoma
Lin, D., Meng, X., Hazawa, M., Nagata, Y., Varela, A. M., Xu, L., Sato, Y., Liu, L., Ding, L., Sharma, A., et al. (2014) · Nature Genetics · doi:10.1038/ng.3006 · Cited by 371
Rickinson, A. B., Young, L. S., & Rowe, M. (1987) · Journal of Virology · doi:10.1128/jvi.61.5.1310-1317.1987 · Cited by 369
The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma
Park, S., Lee, J., Ko, Y. H., Han, A., Jun, H. J., Lee, S. C., Hwang, I. G., Park, Y. H., Ahn, J. S., Jung, C. W., et al. (2007) · Blood · doi:10.1182/blood-2007-01-067769 · Cited by 320
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Rickert, R. C. (2013) · Nature reviews. Immunology · doi:10.1038/nri3487 · Cited by 307
Geographical prevalence of two types of Epstein-Barr virus
Zimber, U., Adldinger, H. K., Lenoir, G., Vuillaume, M., Doeberitz, M. V. K., Laux, G., Des̀granges, C., Wittmann, P., Freese, U. K., Schneider, U., et al. (1986) · Virology · doi:10.1016/0042-6822(86)90429-0 · Cited by 290
DDX3 DEAD-Box RNA Helicase Is Required for Hepatitis C Virus RNA Replication
Ariumi, Y., Kuroki, M., Abe, K.-I., Dansako, H., Ikeda, M., Wakita, T., & Kato, N. (2007) · Journal of Virology · doi:10.1128/jvi.01517-07 · Cited by 259
Kelly, G. L., Bell, A. I., & Rickinson, A. B. (2002) · Nature Medicine · doi:10.1038/nm758 · Cited by 228
Lo, K. W., Chung, G. T., & To, K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.011 · Cited by 219
Young, L. S., Yao, Q. Y., Rooney, C. M., Sculley, T. B., Moss, D. J., Rupani, H., Laux, G., Bornkamm, G. W., & Rickinson, A. B. (1987) · Journal of General Virology · doi:10.1099/0022-1317-68-11-2853 · Cited by 204
Jarrett, R. F., Stark, G. L., White, J. M., Angus, B., Alexander, F. E., Krajewski, A. S., Freeland, J. M. L., Taylor, G. M., Taylor, P. R. A., & for the Scotland and Newcastle Epidemiology of Hodgkin Disease Study Group (2005) · Blood · doi:10.1182/blood-2004-09-3759 · Cited by 199
Impact of HTLV-I Tax on cell cycle progression and the cellular DNA damage repair response
Marriott, S. J., & Semmes, O. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208976 · Cited by 188
Distinct Viral and Mutational Spectrum of Endemic Burkitt Lymphoma
Abate, F., Ambrosio, M. R., Mundo, L., Laginestra, M. A., Fuligni, F., Rossi, M., Zairis, S., Gazaneo, S., Falco, G. D., Lazzi, S., et al. (2015) · PLoS Pathogens · doi:10.1371/journal.ppat.1005158 · Cited by 174
Rowe, M., Young, L. S., Cadwallader, K. A., Petti, L. M., Kieff, E., & Rickinson, A. B. (1989) · Journal of Virology · doi:10.1128/jvi.63.3.1031-1039.1989 · Cited by 172
Lymphoma‐ and leukemia‐associated chromosomal translocations in healthy individuals
Janz, S., Potter, M., & Rabkin, C. S. (2003) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10178 · Cited by 149
Teng, B., Murthy, K. S., Kuemmerle, J. F., Grider, J. R., Sase, K., Michel, T. M., & Makhlouf, G. M. (1998) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1998.275.2.g342 · Cited by 133
Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
Piccaluga, P. P., Falco, G. D., Kustagi, M., Gazzola, A., Agostinelli, C., Tripodo, C., Leucci, E., Onnis, A., Astolfi, A., Sapienza, M. R., et al. (2011) · Blood · doi:10.1182/blood-2010-08-301556 · Cited by 128
MALIGNANT LYMPHOMA IN AFRICAN CHILDREN
Burkitt, D. P. (1961) · The Lancet · doi:10.1016/s0140-6736(61)92052-9 · Cited by 128
Zhang, Z., Theurkauf, W. E., Weng, Z., & Zamore, P. D. (2012) · Silence · doi:10.1186/1758-907x-3-9 · Cited by 122
Modulation of the Cell Growth Regulator mTOR by Epstein-Barr Virus-Encoded LMP2A
Moody, C. A., Scott, R. S., Amirghahari, N., Nathan, C. O., Young, L. S., Dawson, C., & Sixbey, J. W. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5499-5506.2005 · Cited by 119
The role of the proteasome activator PA28 in MHC class I antigen processing
Sijts, A. J. A. M., Sun, Y., Janek, K., Kral, S., Paschen, A., Schadendorf, D., & Kloetzel, P. (2002) · Molecular Immunology · doi:10.1016/s0161-5890(02)00099-8 · Cited by 110
Heikkinen, K., Karppinen, S., Soini, Y., Mäkinen, M., & Winqvist, R. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.12.e131 · Cited by 110
Mathieu, A., Verronèse, E., Rice, G., Fouyssac, F., Bertrand, Y., Pïcard, C., Cruz, M. C. D., Walter, J. E., Notarangelo, L. D., Butte, M. J., et al. (2015) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.01.040 · Cited by 109
Zani, V. J., Asou, N., Jadayel, D. M., Heward, J., SHIPLEY, J. M., Nacheva, E. P., Takasuki, K., Catovsky, D., & Dyer, M. J. S. (1996) · Blood · doi:10.1182/blood.v87.8.3124.bloodjournal8783124 · Cited by 104
Forte, E., Salinas, R. E., Chang, C., Zhou, T., Linnstaedt, S. D., Gottwein, E., Jacobs, C., Jima, D., Li, Q.-J., Dave, S. S., et al. (2012) · Journal of Virology · doi:10.1128/jvi.07056-11 · Cited by 97
Jung, P., & Hermeking, H. (2009) · Cell Cycle · doi:10.4161/cc.8.7.7949 · Cited by 94
The tumor virus landscape of AIDS-related lymphomas
Arvey, A. J., Ojesina, A. I., Pedamallu, C. S., Ballon, G., Jung, J., Duke, F. F., Leoncini, L., Falco, G. D., Bressman, E., Tam, W., et al. (2015) · Blood · doi:10.1182/blood-2014-11-599951 · Cited by 91
Boerma, E.-J. G., Imhoff, G. W. V., Appel, I. M., Veeger, N. J. G. M., Kluin, P. M., & Kluin‐Nelemans, H. C. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.09.004 · Cited by 87
Ambrosio, M. R., Navari, M., Lisio, L. D., Andrés‐León, E., Onnis, A., Gazaneo, S., Mundo, L., Ulivieri, C., Goméz-López, G., Lazzi, S., et al. (2014) · Infectious Agents and Cancer · doi:10.1186/1750-9378-9-12 · Cited by 80
Blenk, S., Engelmann, J. C., Weniger, M., Schultz, J., Dittrich, M. T., Rosenwald, A., Müller‐Hermelink, H. K., Müller, T., & Dandekar, T. (2007) · Cancer Informatics · doi:10.1177/117693510700300004 · Cited by 72
Children with endemic Burkitt lymphoma are deficient in EBNA1‐specific IFN‐γ T cell responses
Moormann, A. M., Heller, K. N., Chelimo, K., Embury, P., Ploutz-Snyder, R. J., Otieno, J. A., Oduor, M., Münz, C., & Rochford, R. A. (2008) · International Journal of Cancer · doi:10.1002/ijc.24014 · Cited by 67
Self-citationYao, Q. Y., Croom-Carter, D. S. G., Tierney, R. J., Habeshaw, G., Wilde, J., Hill, F. G. H., Conlon, C. P., & Rickinson, A. B. (1998) · Journal of Virology · doi:10.1128/jvi.72.5.4352-4363.1998 · Cited by 66
High Prevalence of Epstein‐Barr Virus Type 2 among Homosexual Men Is Caused by Sexual Transmission
van Baarle, D., Hovenkamp, E., Dukers–Muijrers, N. H. T. M., Renwick, N. M., Kersten, M. J., Goudsmit, J., Coutinho, R. A., Miedema, F. F., & van Oers, M. H. J. (2000) · The Journal of Infectious Diseases · doi:10.1086/315521 · Cited by 63
Cai, L., Li, J., Zhang, X., Lu, Y., Wang, J., Lyu, X., Chen, Y., Liu, J., Cai, H., Wang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3046 · Cited by 62
Buckle, G. C., Maranda, L., Skiles, J. L., Ong’echa, J. M., Foley, J., Epstein, M. M., Vik, T. A., Schroeder, A., Lemberger, J., Rosmarin, A. G., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30170 · Cited by 56
Self-citationAsito, A. S., Piriou, E., Odada, P. S., Fiore, N. C., Middeldorp, J. M., Long, C. A., Dutta, S., Lanar, D. E., Jura, W. G. Z. O., Ouma, C., et al. (2010) · Infectious Agents and Cancer · doi:10.1186/1750-9378-5-13 · Cited by 54
Self-citationHIV-associated malignant lymphomas in Kenya (Equatorial Africa)
Lazzi, S., Ferrari, F., Nyong'o, A. O., Palummo, N., Milito, A. D., Zazzi, M., Leoncini, L., Luzi, P., & Tosi, P. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90258-1 · Cited by 54
The PI3K/Akt Pathway as a Target in the Treatment of Hematologic Malignancies
Kawauchi, K., Ogasawara, T., Yasuyama, M., Otsuka, K., & Yamada, O. (2009) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152009788451851 · Cited by 52
Long term survival of children with Burkitt lymphoma in Malawi after cyclophosphamide monotherapy
Kazembe, P. N., Hesseling, P. B., Griffin, B. E., Lampert, I. A., & Wessels, G. (2002) · Medical and Pediatric Oncology · doi:10.1002/mpo.10190 · Cited by 50
Tsujimoto, K., Ono, T., Sato, M., Nishida, T., Oguma, T., & Tadakuma, T. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501304200 · Cited by 49
Yang, H.-J., Huang, T., Yang, C.-F., Peng, L.-X., Liu, R., Yang, G.-D., Chu, Q.-Q., Huang, J.-L., Liu, N., Huang, H.-B., et al. (2013) · Virology Journal · doi:10.1186/1743-422x-10-314 · Cited by 48
Epstein-Barr Virus (EBV)-positive Sporadic Burkitt Lymphoma
Satou, A., Asano, N., Nakazawa, A., Osumi, T., Tsurusawa, M., Ishiguro, A., Elsayed, A. A., Nakamura, N., Ohshima, K., Kinoshita, T., et al. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000332 · Cited by 43
Yang, D., Chen, W., Xiong, J., Sherrod, C. J., Henry, D. H., & Dittmer, D. P. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405423111 · Cited by 42
Navari, M., Etebari, M., Falco, G. D., Ambrosio, M. R., Gibellini, D., Leoncini, L., & Piccaluga, P. P. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00556 · Cited by 34
Clinical characteristics of Burkitt's lymphoma seen in Kenyan patients
Mwanda, O. (2004) · East African Medical Journal · doi:10.4314/eamj.v81i8.9211 · Cited by 33
Okkels, H., Lindorff‐Larsen, K., Thorlacius‐Ussing, O., Vyberg, M., Lindebjerg, J., Sunde, L., Bernstein, I., Klarskov, L. L., Holck, S., & Krarup, H. B. (2012) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0b013e318249739b · Cited by 21
Fujita, S., Buziba, N. G., Kumatori, A., Senba, M., Yamaguchi, A., & Toriyama, K. (2004) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2004-128-549-esoevl · Cited by 21
EBV-associated Burkitt lymphoma in Taiwan is not age-related
Chen, B., Chang, S.-T., Weng, S., Huang, W., Chu, P., Hsieh, P., Jung, Y.-C., Kuo, C.-C., Chuang, Y.-T., & Chuang, S. (2015) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2015.1076928 · Cited by 11
Cited by
Sorted by citations
Alaggio, R., Amador, C., Anagnostopoulos, I., Attygalle, A. D., Araújo, I., Berti, E., Bhagat, G., Borges, A. M., Boyer, D. F., Calaminici, M., et al. (2022) · Leukemia · doi:10.1038/s41375-022-01620-2 · Cited by 4,059
Epstein–Barr virus-associated lymphomas
Shannon-Lowe, C. D., Rickinson, A. B., & Bell, A. I. (2017) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2016.0271 · Cited by 427
Grande, B. M., Gerhard, D. S., Jiang, A., Griner, N. B., Abramson, J. S., Alexander, T., Allen, H., Ayers, L. W., Bethony, J., Bhatia, K. G., et al. (2019) · Blood · doi:10.1182/blood-2018-09-871418 · Cited by 281
MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment
Bian, L., Meng, Y., Zhang, M., & Li, D. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1100-5 · Cited by 267
The whole-genome landscape of Burkitt lymphoma subtypes
Panea, R., Love, C., Shingleton, J. R., Reddy, A., Bailey, J. A., Moormann, A. M., Otieno, J. A., Ong’echa, J. M., Oduor, C. I., Schroeder, K., et al. (2019) · Blood · doi:10.1182/blood.2019001880 · Cited by 194
Self-citation
Metadata
- Authors
- Kaymaz, Y., Oduor, C. I., Yu, H., Otieno, J. A., Ong'echa, J. M., Moormann, A. M., & Bailey, J. A.
- Affiliations
- University of Massachusetts Chan Medical School (US)
- Maseno University (KE)
- Ministry of Health (KE)
- 2Center for Global Health Research, Kenya Medical Research Institute, Kisumu, Kenya.
- Corresponding author
- Bailey, Jeffrey A.
- Venue
- Molecular Cancer Research
- Published
- 2017-05-01
- Volume
- 15
- Issue
- 5
- Pages
- 563-576
- ISSN
- 1541-7786 (ISSN-L)
- 1557-3125
- PMC
- PMC5471630
- OpenAlex
- W2580872164
- Cited by
- 120
- References
- 65
- Citations by year
- 2026: 10 · 2025: 11 · 2024: 17 · 2023: 23 · 2022: 16 · 2021: 14 · 2020: 11 · 2019: 9 · 2018: 4 · 2017: 5
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- National Institutes of Health (UL1TR001453, UL1TR000161)
- National Cancer Institute (R01CA134051, R01CA189806)
- National Institute of Allergy and Infectious Diseases (R01AI099473)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Viral-associated cancers and disorders
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- endemic Burkitt lymphoma, sporadic Burkitt lymphoma, Epstein-Barr virus, transcriptome, mutational profiling, immunoproteasome, PSMB9, TFAP4, MSH6, prognostic factors, pediatric lymphoma
- MeSH terms
- Adolescent, Burkitt Lymphoma, Child, Child, Preschool, Herpesvirus 4, Human, Female, Humans, Kenya, Male, Mutation, Genome, Viral, Sequence Analysis, RNA, Endemic Diseases, Epstein-Barr Virus Infections, Gene Expression Profiling, Gene Regulatory Networks, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
